From sheep to mice to cells: Tools for the study of the sphingolipidoses

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1841, Issue 8, 2014, Pages 1189-1199

  Zigdon, Hila ^a   Meshcheriakova, Anna ^a   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cell culture; Large animal model; Lysosomal storage disorder; Mouse model; Sphingolipid

Indexed keywords

GALACTOSYLCERAMIDASE; LIPID; PHOSPHOLIPASE A2; SPHINGOMYELIN PHOSPHODIESTERASE;

APOPTOSIS; BEHAVIOR DISORDER; CELL INTERACTION; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; DISEASE SEVERITY; DYSTONIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; EXPERIMENTAL MOUSE; FABRY DISEASE; FACE MALFORMATION; FARBER DISEASE; GAIT DISORDER; GAUCHER DISEASE; GENE MUTATION; GENETIC MANIPULATION; GLOBOID CELL LEUKODYSTROPHY; GM1 GANGLIOSIDOSIS; GM2 GANGLIOSIDOSIS; HEART DISEASE; HUMAN; KIDNEY DISEASE; LIPID HYDROLYSIS; LIPID RAFT; LYSOSOME STORAGE DISEASE; MENTAL DEFICIENCY; METACHROMATIC LEUKODYSTROPHY; MISSENSE MUTATION; MUSCLE WEAKNESS; NIEMANN PICK DISEASE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SANDHOFF DISEASE; SEIZURE; SHORT STATURE; SKELETON MALFORMATION; SKIN PERMEABILITY; SLURRED SPEECH; TREMOR; UNFOLDED PROTEIN RESPONSE; VERTEBRA MALFORMATION; WEAKNESS; WEIGHT REDUCTION;

ANIMALIA; MAMMALIA; MUS; OVIS ARIES;

CELL CULTURE; LARGE ANIMAL MODEL; LYSOSOMAL STORAGE DISORDER; MOUSE MODEL; SPHINGOLIPID;

ANIMALS; DISEASE MODELS, ANIMAL; MICE; SHEEP; SPHINGOLIPIDOSES;

EID: 84903276555     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2014.02.008     Document Type: Review

References (198)

1. S. Lahiri, and A.H. Futerman The metabolism and function of sphingolipids and glycosphingolipids Cell. Mol. Life Sci. 64 2007 2270 2284 (Pubitemid 47347954)
2. A.H. Futerman, and G. van Meer The cell biology of lysosomal storage disorders Nat. Rev. Mol. Cell Biol. 5 2004 554 565 (Pubitemid 38868584)
3. M. Eckhardt Pathology and current treatment of neurodegenerative sphingolipidoses Neruomol. Med. 12 2010 362 382
4. L. Ginzburg, Y. Kacher, and A.H. Futerman The pathogenesis of glycosphingolipid storage disorders Semin. Cell Dev. Biol. 15 2004 417 431 (Pubitemid 38781904)
5. E.F. Neufeld Lysosomal storage diseases Annu. Rev. Biochem. 60 1991 257 280
6. E.B. Vitner, F.M. Platt, and A.H. Futerman Common and uncommon pathogenic cascades in lysosomal storage diseases J. Biol. Chem. 285 2010 20423 20427
7. T. Farfel-Becker, E. Vitner, H. Dekel, N. Leshem, I.B. Enquist, S. Karlsson, and A.H. Futerman No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease Hum. Mol. Genet. 18 2009 1482 1488
8. K.W. Radcliffe, and B.A. Evans Anderson-Fabry disease (angiokeratoma corporis diffusum universale) Genitourin. Med. 66 1990 399 400 (Pubitemid 20355687)
9. P.J. Meikle, J.J. Hopwood, A.E. Clague, and W.F. Carey Prevalence of lysosomal storage disorders JAMA 281 1999 249 254 (Pubitemid 29058114)
10. H.A. Ozkara, and M. Topcu Sphingolipidoses in Turkey Brain Dev. 26 2004 363 366 (Pubitemid 38953321)
11. M.G. Haskins U Patterson, DF, animal models of lysosomal storage diseases: their development and clinical relevance 2006 Oxford PharmaGenesis Oxford
12. A.H. Futerman, and A. Zimran Gaucher Disease 2006 CRC Press, Taylor and Francis Group Boca Raton, FL.
13. Y. Sun, W. Zhang, Y.H. Xu, B. Quinn, N. Dasgupta, B. Liou, K.D. Setchell, and G.A. Grabowski Substrate compositional variation with tissue/region and Gba1 mutations in mouse models - implications for Gaucher disease PLoS One 8 2013 e57560
14. A. Tylki-Szymanska, B. Czartoryska, M.T. Vanier, B.J. Poorthuis, J.A. Groener, A. Lugowska, G. Millat, A.M. Vaccaro, and E. Jurkiewicz Non-neuronopathic Gaucher disease due to saposin C deficiency Clin. Genet. 72 2007 538 542 (Pubitemid 350131059)
15. R.J. Tamargo, A. Velayati, E. Goldin, and E. Sidransky The role of saposin C in Gaucher disease Mol. Genet. Metab. 106 2012 257 263
16. J.S. O'Brien, and Y. Kishimoto Saposin proteins: structure, function, and role in human lysosomal storage disorders FASEB J. 5 1991 301 308 (Pubitemid 21892890)
17. G.A. Grabowski Gaucher disease: gene frequencies and genotype/phenotype correlations Genet. Test. 1 1997 5 12 (Pubitemid 127526931)
18. T. Shachar, C. Lo Bianco, A. Recchia, C. Wiessner, A. Raas-Rothschild, and A.H. Futerman Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond Mov. Disord. 26 2011 1593 1604
19. E. Sidransky, M.A. Nalls, J.O. Aasly, J. Aharon-Peretz, G. Annesi, E.R. Barbosa, A. Bar-Shira, D. Berg, J. Bras, A. Brice, C.M. Chen, L.N. Clark, C. Condroyer, E.V. De Marco, A. Durr, M.J. Eblan, S. Fahn, M.J. Farrer, H.C. Fung, Z. Gan-Or, T. Gasser, R. Gershoni-Baruch, N. Giladi, A. Griffith, T. Gurevich, C. Januario, P. Kropp, A.E. Lang, G.J. Lee-Chen, S. Lesage, K. Marder, I.F. Mata, A. Mirelman, J. Mitsui, I. Mizuta, G. Nicoletti, C. Oliveira, R. Ottman, A. Orr-Urtreger, L.V. Pereira, A. Quattrone, E. Rogaeva, A. Rolfs, H. Rosenbaum, R. Rozenberg, A. Samii, T. Samaddar, C. Schulte, M. Sharma, A. Singleton, M. Spitz, E.K. Tan, N. Tayebi, T. Toda, A.R. Troiano, S. Tsuji, M. Wittstock, T.G. Wolfsberg, Y.R. Wu, C.P. Zabetian, Y. Zhao, and S.G. Ziegler Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease N. Engl. J. Med. 361 2009 1651 1661
20. T. Farfel-Becker, E.B. Vitner, and A.H. Futerman Animal models for Gaucher disease research Dis. Model. Mech. 4 2011 746 752
21. L. Premkumar, A.R. Sawkar, S. Boldin-Adamsky, L. Toker, I. Silman, J.W. Kelly, A.H. Futerman, and J.L. Sussman X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide J. Biol. Chem. 280 2005 23815 23819 (Pubitemid 40884867)
22. J.N. Kanfer, G. Legler, J. Sullivan, S.S. Raghavan, and R.A. Mumford The Gaucher mouse Biochem. Biophys. Res. Commun. 67 1975 85 90
23. S. Atsumi, C. Nosaka, H. Iinuma, and K. Umezawa Inhibition of glucocerebrosidase and induction of neural abnormality by cyclophellitol in mice Arch. Biochem. Biophys. 297 1992 362 367 (Pubitemid 23282893)
24. S. Atsumi, C. Nosaka, H. Iinuma, and K. Umezawa Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol Arch. Biochem. Biophys. 304 1993 302 304 (Pubitemid 23214185)
25. Y.H. Xu, R. Reboulet, B. Quinn, J. Huelsken, D. Witte, and G.A. Grabowski Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels Mol. Genet. Metab. 94 2008 190 203
26. V.L. Tybulewicz, M.L. Tremblay, M.E. LaMarca, R. Willemsen, B.K. Stubblefield, S. Winfield, B. Zablocka, E. Sidransky, B.M. Martin, and S.P. Huang et al. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene Nature 357 1992 407 410
27. I.B. Enquist, C. Lo Bianco, A. Ooka, E. Nilsson, J.E. Mansson, M. Ehinger, J. Richter, R.O. Brady, D. Kirik, and S. Karlsson Murine models of acute neuronopathic Gaucher disease Proc. Natl. Acad. Sci. U. S. A. 104 2007 17483 17488 (Pubitemid 350219864)
28. T. Farfel-Becker, E.B. Vitner, S.L. Kelly, J.R. Bame, J. Duan, V. Shinder, A.H. Merrill Jr., K. Dobrenis, and A.H. Futerman Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration Hum. Mol. Genet. 23 2013 843 854
29. T. Farfel-Becker, E.B. Vitner, S.N. Pressey, R. Eilam, J.D. Cooper, and A.H. Futerman Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease Hum. Mol. Genet. 20 2011 1375 1386
30. E.B. Vitner, H. Dekel, H. Zigdon, T. Shachar, T. Farfel-Becker, R. Eilam, S. Karlsson, and A.H. Futerman Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses Hum. Mol. Genet. 19 2010 3583 3590
31. E.B. Vitner, T. Farfel-Becker, R. Eilam, I. Biton, and A.H. Futerman Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease Brain 135 2012 1724 1735
32. E.B. Vitner, R. Salomon, T. Farfel-Becker, A. Meshcheriakova, M. Ali, A.D. Klein, F.M. Platt, T.M. Cox, and A.H. Futerman RIP3 as a novel potential therapeutic target for Gaucher disease Nat. Med. 20 2014 204 208
33. Y.H. Xu, B. Quinn, D. Witte, and G.A. Grabowski Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease Am. J. Pathol. 163 2003 2093 2101 (Pubitemid 37310038)
34. Y. Liu, K. Suzuki, J.D. Reed, A. Grinberg, H. Westphal, A. Hoffmann, T. Doring, K. Sandhoff, and R.L. Proia Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure Proc. Natl. Acad. Sci. U. S. A. 95 1998 2503 2508 (Pubitemid 28145971)
35. H. Mizukami, Y. Mi, R. Wada, M. Kono, T. Yamashita, Y. Liu, N. Werth, R. Sandhoff, K. Sandhoff, and R.L. Proia Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage J. Clin. Invest. 109 2002 1215 1221 (Pubitemid 34496599)
36. P.K. Mistry, J. Liu, M. Yang, T. Nottoli, J. McGrath, D. Jain, K. Zhang, J. Keutzer, W.L. Chuang, W.Z. Mehal, H. Zhao, A. Lin, S. Mane, X. Liu, Y.Z. Peng, J.H. Li, M. Agrawal, L.L. Zhu, H.C. Blair, L.J. Robinson, J. Iqbal, L. Sun, and M. Zaidi Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage Proc. Natl. Acad. Sci. U. S. A. 107 2010 19473 19478
37. I.B. Enquist, E. Nilsson, A. Ooka, J.E. Mansson, K. Olsson, M. Ehinger, R.O. Brady, J. Richter, and S. Karlsson Effective cell and gene therapy in a murine model of Gaucher disease Proc. Natl. Acad. Sci. U. S. A. 103 2006 13819 13824 (Pubitemid 44413991)
38. G.B. Sinclair, G. Jevon, K.E. Colobong, D.R. Randall, F.Y. Choy, and L.A. Clarke Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease Mol. Genet. Metab. 90 2007 148 156 (Pubitemid 46108614)
39. E. Beutler, C. West, B.E. Torbett, and H. Deguchi A chimeric mouse model of Gaucher disease Mol. Med. 8 2002 247 250
40. Y. Sun, H. Ran, M. Zamzow, K. Kitatani, M.R. Skelton, M.T. Williams, C.V. Vorhees, D.P. Witte, Y.A. Hannun, and G.A. Grabowski Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse Hum. Mol. Genet. 19 2010 634 647
41. Y. Sun, X. Qi, D.P. Witte, E. Ponce, K. Kondoh, B. Quinn, and G.A. Grabowski Prosaposin: threshold rescue and analysis of the " neuritogenic" region in transgenic mice Mol. Genet. Metab. 76 2002 271 286
42. Y. Sun, B. Quinn, D.P. Witte, and G.A. Grabowski Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants J. Lipid Res. 46 2005 2102 2113 (Pubitemid 41377462)
43. V. Cullen, S.P. Sardi, J. Ng, Y.H. Xu, Y. Sun, J.J. Tomlinson, P. Kolodziej, I. Kahn, P. Saftig, J. Woulfe, J.C. Rochet, M.A. Glicksman, S.H. Cheng, G.A. Grabowski, L.S. Shihabuddin, and M.G. Schlossmacher Acid beta-glucosidase mutants linked to Gaucher disease. Parkinson disease, and Lewy body dementia alter alpha-synuclein processing Ann. Neurol. 69 2011 940 953
44. Y. Sun, B. Quinn, Y.H. Xu, T. Leonova, D.P. Witte, and G.A. Grabowski Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse model J. Lipid Res. 47 2006 2161 2170 (Pubitemid 44936126)
45. A. Sanders, H. Hemmelgarn, H.L. Melrose, L. Hein, M. Fuller, and L.A. Clarke Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease Blood Cells Mol. Dis. 51 2013 109 115
46. W.J. Hartley, and W.F. Blakemore Neurovisceral glucocerebroside storage (Gaucher's disease) in a dog Vet. Pathol. 10 1973 191 201
47. A.T. Sandison, and L.J. Anderson Histiocytosis in two pigs and a cow: conditions resembling lipid storage disorders in man J. Pathol. 100 1970 207 210
48. L. Laws, and J.R. Saal Lipidosis of the hepatic reticulo-endothelial cells in a sheep Aust. Vet. J. 44 1968 416 417
49. L. Karageorgos, M.J. Lancaster, J.S. Nimmo, and J.J. Hopwood Gaucher disease in sheep J. Inherit. Metab. Dis. 34 2011 209 215
50. L.K. Hein, P.J. Meikle, J.J. Hopwood, and M. Fuller Secondary sphingolipid accumulation in a macrophage model of Gaucher disease Mol. Genet. Metab. 92 2007 336 345 (Pubitemid 350117716)
51. M. Lamghari, C.C. Barrias, C. Sa Miranda, and M.A. Barbosa Recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model Blood Cells Mol. Dis. 35 2005 348 354 (Pubitemid 41630720)
52. D. Pelled, H. Shogomori, and A.H. Futerman The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase J. Inherit. Metab. Dis. 23 2000 175 184 (Pubitemid 30198120)
53. E.M. Prence, P. Chaturvedi, and D.S. Newburg In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology J. Neurosci. Res. 43 1996 365 371 (Pubitemid 26054023)
54. Y. Kacher, A. Golan, Y. Pewzner-Jung, and A.H. Futerman Changes in macrophage morphology in a Gaucher disease model are dependent on CTP: phosphocholine cytidylyltransferase alpha Blood Cells Mol. Dis. 39 2007 124 129 (Pubitemid 46754932)
55. S. Trajkovic-Bodennec, J. Bodennec, and A.H. Futerman Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes Blood Cells Mol. Dis. 33 2004 77 82 (Pubitemid 38829602)
56. B. Hardy, B. Teitelman-Weissman, S. Chazan, and A. Neri Glucocerebroside storage in normal monocyte cultures Biomed. Pharmacother. 41 1987 40 44 (Pubitemid 17083967)
57. U.H. Schueler, T. Kolter, C.R. Kaneski, J.K. Blusztajn, M. Herkenham, K. Sandhoff, and R.O. Brady Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3 Neurobiol. Dis. 14 2003 595 601 (Pubitemid 37543536)
58. E. Lloyd-Evans, D. Pelled, C. Riebeling, and A.H. Futerman Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms Biochem. J. 375 2003 561 565 (Pubitemid 37433504)
59. L.M. Panicker, D. Miller, T.S. Park, B. Patel, J.L. Azevedo, O. Awad, M.A. Masood, T.D. Veenstra, E. Goldin, B.K. Stubblefield, N. Tayebi, S.K. Polumuri, S.N. Vogel, E. Sidransky, E.T. Zambidis, and R.A. Feldman Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease Proc. Natl. Acad. Sci. U. S. A. 109 2012 18054 18059
60. P.J. Paddison, A.A. Caudy, E. Bernstein, G.J. Hannon, and D.S. Conklin Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells Genes Dev 16 2002 948 958 (Pubitemid 34408544)
61. G.A. Ashley, J. Shabbeer, M. Yasuda, C.M. Eng, and R.J. Desnick Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype J. Hum. Genet. 46 2001 192 196 (Pubitemid 32435602)
62. C.M. Eng, and R.J. Desnick Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene Hum. Mutat. 3 1994 103 111 (Pubitemid 24077226)
63. C. Masson, I. Cisse, V. Simon, P. Insalaco, and M. Audran Fabry disease: a review Joint Bone Spine 71 2004 381 383 (Pubitemid 39335671)
64. T. Ohshima, G.J. Murray, W.D. Swaim, G. Longenecker, J.M. Quirk, C.O. Cardarelli, Y. Sugimoto, I. Pastan, M.M. Gottesman, R.O. Brady, and A.B. Kulkarni Alpha-galactosidase A deficient mice: a model of Fabry disease Proc. Natl. Acad. Sci. U. S. A. 94 1997 2540 2544 (Pubitemid 27136911)
65. A. Nguyen Dinh Cat, B. Escoubet, V. Agrapart, V. Griol-Charhbili, T. Schoeb, W. Feng, E. Jaimes, D.G. Warnock, and F. Jaisser Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry disease PLoS One 7 2012 e33743
66. L.G. Rodrigues, M.J. Ferraz, D. Rodrigues, M. Pais-Vieira, D. Lima, R.O. Brady, M.M. Sousa, and M.C. Sa-Miranda Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice Neurobiol. Dis. 33 2009 48 56
67. C. Valbuena, J.P. Oliveira, F. Carneiro, S. Relvas, M. Ganhao, M.C. Sa-Miranda, and L.G. Rodrigues Kidney histologic alterations in alpha-Galactosidase-deficient mice Virchows Arch. 458 2011 477 486
68. M. Shimmoto, R. Kase, K. Itoh, K. Utsumi, S. Ishii, C. Taya, H. Yonekawa, and H. Sakuraba Generation and characterization of transgenic mice expressing a human mutant alpha-galactosidase with an R301Q substitution causing a variant form of Fabry disease FEBS Lett. 417 1997 89 91 (Pubitemid 27490479)
69. S. Ishii, H. Yoshioka, K. Mannen, A.B. Kulkarni, and J.Q. Fan Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease Biochim. Biophys. Acta 1690 2004 250 257 (Pubitemid 39423620)
70. T. Thomaidis, M. Relle, M. Golbas, C. Brochhausen, P.R. Galle, M. Beck, and A. Schwarting Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy Kidney Int. 75 2009 399 407
71. M.C. Liebau, F. Braun, K. Hopker, C. Weitbrecht, V. Bartels, R.U. Muller, S. Brodesser, M.A. Saleem, T. Benzing, B. Schermer, M. Cybulla, and C.E. Kurschat Dysregulated autophagy contributes to podocyte damage in Fabry's disease PLoS One 8 2013 e63506
72. J.S. Shen, X.L. Meng, R. Schiffmann, R.O. Brady, and C.R. Kaneski Establishment and characterization of Fabry disease endothelial cells with an extended lifespan Mol. Genet. Metab. 92 2007 137 144 (Pubitemid 47371101)
73. X.L. Meng, J.S. Shen, S. Kawagoe, T. Ohashi, R.O. Brady, and Y. Eto Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders Proc. Natl. Acad. Sci. U. S. A. 107 2010 7886 7891
74. V. Gieselmann Metachromatic leukodystrophy: recent research developments J. Child Neurol. 18 2003 591 594 (Pubitemid 37258463)
75. L. Kuchar, J. Ledvinova, M. Hrebicek, H. Myskova, L. Dvorakova, L. Berna, P. Chrastina, B. Asfaw, M. Elleder, M. Petermoller, H. Mayrhofer, M. Staudt, I. Krageloh-Mann, B.C. Paton, and K. Harzer Prosaposin deficiency and saposin B deficiency (activator-deficient metachromatic leukodystrophy): report on two patients detected by analysis of urinary sphingolipids and carrying novel PSAP gene mutations Am. J. Med. Genet. A 149A 2009 613 621
76. S. Grossi, S. Regis, C. Rosano, F. Corsolini, G. Uziel, M. Sessa, M. Di Rocco, G. Parenti, F. Deodato, V. Leuzzi, R. Biancheri, and M. Filocamo Molecular analysis of ARSA and PSAP genes in twenty-one Italian patients with metachromatic leukodystrophy: identification and functional characterization of 11 novel ARSA alleles Hum. Mutat. 29 2008 E220 E230
77. V. Gieselmann, U. Matzner, B. Hess, R. Lullmann-Rauch, R. Coenen, D. Hartmann, R. D'Hooge, P. DeDeyn, and G. Nagels Metachromatic leukodystrophy: molecular genetics and an animal model J. Inherit. Metab. Dis. 21 1998 564 574 (Pubitemid 28391508)
78. B. Hess, P. Saftig, D. Hartmann, R. Coenen, R. Lullmann-Rauch, H.H. Goebel, M. Evers, K. von Figura, R. D'Hooge, G. Nagels, P. De Deyn, C. Peters, and V. Gieselmann Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy Proc. Natl. Acad. Sci. U. S. A. 93 1996 14821 14826 (Pubitemid 26419053)
79. H. Ramakrishnan, K.K. Hedayati, R. Lullmann-Rauch, C. Wessig, S.N. Fewou, H. Maier, H.H. Goebel, V. Gieselmann, and M. Eckhardt Increasing sulfatide synthesis in myelin-forming cells of arylsulfatase A-deficient mice causes demyelination and neurological symptoms reminiscent of human metachromatic leukodystrophy J. Neurosci. 27 2007 9482 9490 (Pubitemid 47358222)
80. M. Eckhardt, K.K. Hedayati, J. Pitsch, R. Lullmann-Rauch, H. Beck, S.N. Fewou, and V. Gieselmann Sulfatide storage in neurons causes hyperexcitability and axonal degeneration in a mouse model of metachromatic leukodystrophy J. Neurosci. 27 2007 9009 9021 (Pubitemid 47312065)
81. U. Matzner, E. Herbst, K.K. Hedayati, R. Lullmann-Rauch, C. Wessig, S. Schroder, C. Eistrup, C. Moller, J. Fogh, and V. Gieselmann Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy Hum. Mol. Genet. 14 2005 1139 1152 (Pubitemid 40613903)
82. U. Matzner, F. Matthes, E. Herbst, R. Lullmann-Rauch, Z. Callaerts-Vegh, R. D'Hooge, C. Weigelt, C. Eistrup, J. Fogh, and V. Gieselmann Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy Mol. Med. 13 2007 471 479 (Pubitemid 47585741)
83. F. Matthes, S. Stroobants, D. Gerlach, C. Wohlenberg, C. Wessig, J. Fogh, V. Gieselmann, M. Eckhardt, R. D'Hooge, and U. Matzner Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age Hum. Mol. Genet. 21 2012 2599 2609
84. S. Stroobants, D. Gerlach, F. Matthes, D. Hartmann, J. Fogh, V. Gieselmann, R. D'Hooge, and U. Matzner Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy Hum. Mol. Genet. 20 2011 2760 2769
85. Y. Sun, D.P. Witte, H. Ran, M. Zamzow, S. Barnes, H. Cheng, X. Han, M.T. Williams, M.R. Skelton, C.V. Vorhees, and G.A. Grabowski Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice Hum. Mol. Genet. 17 2008 2345 2356
86. K. Saravanan, H. Bussow, N. Weiler, V. Gieselmann, and S. Franken A spontaneously immortalized Schwann cell line to study the molecular aspects of metachromatic leukodystrophy J. Neurosci. Methods 161 2007 223 233 (Pubitemid 46466949)
87. J. Matsuda, M.T. Vanier, Y. Saito, J. Tohyama, and K. Suzuki A mutation in the saposin A domain of the sphingolipid activator protein (prosaposin) gene results in a late-onset, chronic form of globoid cell leukodystrophy in the mouse Hum. Mol. Genet. 10 2001 1191 1199 (Pubitemid 32487542)
88. A. Kohlschutter Lysosomal leukodystrophies: Krabbe disease and metachromatic leukodystrophy Handb. Clin. Neurol. 113 2013 1611 1618
89. I.D. Duncan, Y. Kondo, and S.-C. Zhang The myelin mutants as models to study myelin repair in the leukodystrophies Neurotherapeutics 8 2011 607 624
90. N. Sakai Pathogenesis of leukodystrophy for Krabbe disease: molecular mechanism and clinical treatment Brain Dev. 31 2009 485 487
91. L.W. Duchen, E.M. Eicher, J.M. Jacobs, F. Scaravilli, and F. Teixeira Hereditary leucodystrophy in the mouse: the new mutant twitcher Brain 103 1980 695 710 (Pubitemid 10001187)
92. T. Kobayashi, T. Yamanaka, J.M. Jacobs, F. Teixeira, and K. Suzuki The twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease) Brain Res. 202 1980 479 483 (Pubitemid 11130332)
93. H. Ida, F. Umezawa, E. Kasai, Y. Eto, and K. Maekawa An accumulation of galactocerebroside in kidney from mouse globoid cell leukodystrophy (twitcher) Biochem. Biophys. Res. Commun. 109 1982 634 638 (Pubitemid 13143732)
94. G.B. Potter, M. Santos, M.T. Davisson, D.H. Rowitch, D.L. Marks, E.R. Bongarzone, and M.A. Petryniak Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease Hum. Mol. Genet. 22 2013 3397 3414
95. B. Tappino, R. Biancheri, M. Mort, S. Regis, F. Corsolini, A. Rossi, M. Stroppiano, S. Lualdi, A. Fiumara, B. Bembi, M. Di Rocco, D.N. Cooper, and M. Filocamo Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease Hum. Mutat. 31 2010 E1894 E1914
96. P. Luzi, M.A. Rafi, M. Zaka, M. Curtis, M.T. Vanier, and D.A. Wenger Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease) Mol. Genet. Metab. 73 2001 211 223 (Pubitemid 32709611)
97. T.F. Fletcher, and H.J. Kurtz Animal model: globoid cell leukodystrophy in the dog Am. J. Pathol. 1972 375 378
98. B.G. Boysen Globoid cell leukodystrophy in the bluetick hound dog. 1. Clinical manifestations Can. Vet. J. 15 1974 303 308
99. T. Victoria, M.A. Rafi, and D.A. Wenger Cloning of the canine GALC cDNA and identification of the mutation causing globoid cell leukodystrophy in West Highland White and Cairn terriers Genomics 33 1996 457 462 (Pubitemid 26159861)
100. D.A. Wenger, T. Victoria, M.A. Rafi, P. Luzi, M.T. Vanier, C. Vite, D.F. Patterson, and M.H. Haskins Globoid cell leukodystrophy in cairn and West Highland white terriers J. Hered. 90 1999 138 142 (Pubitemid 29067917)
101. P. Luzi, M.A. Rafi, T. Victoria, G.B. Baskin, and D.A. Wenger Characterization of the rhesus monkey galactocerebrosidase (GALC) cDNA and gene and identification of the mutation causing globoid cell leukodystrophy (Krabbe disease) in this primate Genomics 42 1997 319 324 (Pubitemid 27263763)
102. G.B. Baskin, M. Ratterree, B.B. Davison, K.P. Falkenstein, M.R. Clarke, J.D. England, M.T. Vanier, P. Luzi, M.A. Rafi, and D.A. Wenger Genetic galactocerebrosidase deficiency (globoid cell leukodystrophy, Krabbe disease) in rhesus monkeys (Macaca mulatta) Lab. Anim. Sci. 48 1998 476 482
103. J.T. Borda, X. Alvarez, M. Mohan, M.S. Ratterree, K. Phillippi- Falkenstein, A.a. Lackner, and B.a. Bunnell Clinical and immunopathologic alterations in rhesus macaques affected with globoid cell leukodystrophy The American journal of pathology 172 2008 98 111 (Pubitemid 351186372)
104. D.H. Pritchard, D.V. Napthine, and a.J. Sinclair Globoid cell leucodystrophy in polled Dorset sheep Vet. Pathol. 17 1980 399 405 (Pubitemid 10011414)
105. C. Salvadori, M. Modenato, D.S. Corlazzoli, M. Arispici, and C. Cantile Clinicopathological features of globoid cell leucodystrophy in cats J. Comp. Pathol. 132 2005 350 356 (Pubitemid 40645429)
106. C.J. Sigurdson, R.J. Basaraba, E.M. Mazzaferro, and D.H. Gould Globoid cell-like leukodystrophy in a domestic longhaired cat Vet. Pathol. 39 2002 494 496
107. M. Haskins Gene therapy for lysosomal storage diseases (LSDs) in large animal models ILAR J. 50 2009 112 121
108. K. Suzuki Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status Neurochem. Res. 23 1998 251 259
109. A.B. White, M.I. Givogri, A. Lopez-Rosas, H. Cao, R. van Breemen, G. Thinakaran, and E.R. Bongarzone Psychosine accumulates in membrane microdomains in the brain of krabbe patients, disrupting the raft architecture J. Neurosci. 29 2009 6068 6077
110. S. Giri, M. Khan, R. Rattan, I. Singh, and a.K. Singh Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death J. Lipid Res. 47 2006 1478 1492 (Pubitemid 44079902)
111. S.T. Brady, R.J. Lasek, and R.D. Allen Fast axonal transport in extruded axoplasm from squid giant axon Science 218 1982 1129 1131 (Pubitemid 13223316)
112. L. Cantuti Castelvetri, M.I. Givogri, A. Hebert, B. Smith, Y. Song, A. Kaminska, A. Lopez-Rosas, G. Morfini, G. Pigino, M. Sands, S.T. Brady, and E.R. Bongarzone The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3-β and deregulation of molecular motors J. Neurosci. 33 2013 10048 10056
113. L. Cantuti-Castelvetri, H. Zhu, M.I. Givogri, R.L. Chidavaenzi, A. Lopez-Rosas, and E.R. Bongarzone Psychosine induces the dephosphorylation of neurofilaments by deregulation of PP1 and PP2A phosphatases Neurobiol. Dis. 46 2012 325 335
114. E.H. Schuchman Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease FEBS Lett. 584 2010 1895 1900
115. E. Conzelmann, and K. Sandhoff Partial enzyme deficiencies: residual activities and the development of neurological disorders Dev. Neurosci. 6 1983 58 71 (Pubitemid 14237247)
116. E.H. Schuchman The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease J. Inherit. Metab. Dis. 30 2007 654 663 (Pubitemid 47559876)
117. C.A. Paul, A.K. Boegle, and R.A. Maue Before the loss: neuronal dysfunction in Niemann-Pick type C disease Biochim. Biophys. Acta 1685 2004 63 76 (Pubitemid 39311810)
118. E. Lloyd-Evans, A.J. Morgan, X. He, D.a. Smith, E. Elliot-Smith, D.J. Sillence, G.C. Churchill, E.H. Schuchman, A. Galione, and F.M. Platt Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium Nat. Med. 14 2008 1247 1255
119. B. Otterbach, and W. Stoffel Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease) Cell 81 1995 1053 1061
120. T.A. Kuemmel, J. Thiele, R. Schroeder, and W. Stoffel Pathology of visceral organs and bone marrow in an acid sphingomyelinase deficient knock-out mouse line, mimicking human Niemann-Pick disease type A A light and electron microscopic study Pathol. Res. Pract. 193 1997 663 671 (Pubitemid 28064112)
121. K. Horinouchi, S. Erlich, D.P. Perl, and K. Ferlinz Acid sphingomyelinase deficient mice: a model of types A and B Niemann Pick disease Nat. Genet. 10 1995 288 293
122. S.L. Macauley, R.L. Sidman, E.H. Schuchman, T. Taksir, and G.R. Stewart Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration Exp. Neurol. 214 2008 181 192
123. L. Ginzburg, and A.H. Futerman Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease J. Neurochem. 95 2005 1619 1628 (Pubitemid 41804059)
124. F. Paris, Z. Fuks, A. Kang, P. Capodieci, G. Juan, D. Ehleiter, A. Haimovitz-Friedman, C. Cordon-Cardo, and R. Kolesnick Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 2001 293 297 (Pubitemid 32694744)
125. P. Santana, L.A. Pena, A. Haimovitz-Friedman, S. Martin, D. Green, M. McLoughlin, C. Cordon-Cardo, E.H. Schuchman, Z. Fuks, and R. Kolesnick Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis Cell 86 1996 189 199 (Pubitemid 26286102)
126. A.R. Leventhal, W. Chen, A.R. Tall, and I. Tabas Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux J. Biol. Chem. 276 2001 44976 44983
127. C.P. Reynolds, B.J. Maurer, and R.N. Kolesnick Ceramide synthesis and metabolism as a target for cancer therapy Cancer Lett. 206 2004 169 180 (Pubitemid 38317287)
128. S. Marathe, S.R. Miranda, C. Devlin, a. Johns, G. Kuriakose, K.J. Williams, E.H. Schuchman, and I. Tabas Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function Hum. Mol. Genet. 9 2000 1967 1976 (Pubitemid 30642661)
129. A. Bundza, J.A. Lowden, and K.M. Charlton Niemann-Pick disease in a poodle dog Vet. Pathol. 16 1979 530 538 (Pubitemid 9253961)
130. N. Vapniarsky, D.A. Wenger, D. Scheenstra, and A. Mete Sphingomyelin lipidosis (Niemann-Pick disease) in a juvenile raccoon (Procyon lotor) J. Comp. Pathol. 149 2013 385 389
131. G.K. Saunders, and D.A. Wenger Sphingomyelinase deficiency (Niemann-Pick disease) in a Hereford calf Vet. Pathol. 45 2008 201 202 (Pubitemid 351571655)
132. H.J. Baker, and P.A. Wood Sphingomyelin lipidosis in a cat Vet. Pathol. 24 1987 386 391
133. S.U. Walkley, and H.J. Baker Sphingomyelin lipidosis in a cat: Golgi studies Acta Neuropathol. 65 1984 138 144 (Pubitemid 15221065)
134. D.A. Wenger, M. Sattler, and T. Kudoh Niemann-Pick disease: a genetic model in Siamese cats Science 200 1980 1471 1473 (Pubitemid 10022197)
135. B. Henry, R. Ziobro, K.A. Becker, R. Kolesnick, and E. Gulbins Acid sphingomyelinase Handb. Exp. Pharmacol. 2013 77 88
136. E.H. Schuchman Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease FEBS Lett. 584 2010 1895 1900
137. C. Arenz Small molecule inhibitors of acid sphingomyelinase Cell. Physiol. Biochem. 26 2010 1 8
138. D. Canals, D.M. Perry, R.W. Jenkins, and Y.A. Hannun Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases Br. J. Pharmacol. 163 2010 694 712
139. M.S. Sands Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology EMBO Mol. Med. 5 2013 799 801
140. K. Ehlert, M. Frosch, N. Fehse, A. Zander, J. Roth, and J. Vormoor Farber disease: clinical presentation, pathogenesis and a new approach to treatment Pediatr. Rheumatol. Online J. 5 2007 15
141. N.S. Ferreira, M. Goldschmidt-Arzi, H. Sabanay, J. Storch, T. Levade, M.G. Ribeiro, L. Addadi, and A.H. Futerman Accumulation of ordered ceramide-cholesterol domains in Farber disease fibroblasts JIMD Rep. 2013
142. C.M. Li, J.H. Park, C.M. Simonaro, X. He, R.E. Gordon, A.H. Friedman, D. Ehleiter, F. Paris, K. Manova, S. Hepbildikler, Z. Fuks, K. Sandhoff, R. Kolesnick, and E.H. Schuchman Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes Genomics 79 2002 218 224
143. A.M. Alayoubi, J.C. Wang, B.C. Au, S. Carpentier, V. Garcia, S. Dworski, S. El-Ghamrasni, K.N. Kirouac, M.J. Exertier, Z.J. Xiong, G.G. Prive, C.M. Simonaro, J. Casas, G. Fabrias, E.H. Schuchman, P.V. Turner, R. Hakem, T. Levade, and J.A. Medin Systemic ceramide accumulation leads to severe and varied pathological consequences EMBO Mol. Med. 5 2013 827 842
144. Y.H. Zeidan, R.W. Jenkins, J.B. Korman, X. Liu, L.M. Obeid, J.S. Norris, and Y.A. Hannun Molecular targeting of acid ceramidase: implications to cancer therapy Curr. Drug Targets 9 2008 653 661
145. E. Eliyahu, N. Shtraizent, R. Shalgi, and E.H. Schuchman Construction of conditional acid ceramidase knockout mice and in vivo effects on oocyte development and fertility Cell. Physiol. Biochem. 30 2012 735 748
146. M. Selzner, A. Bielawska, M.A. Morse, H.A. Rudiger, D. Sindram, Y.A. Hannun, and P.A. Clavien Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer Cancer Res. 61 2001 1233 1240 (Pubitemid 32174448)
147. N. Brunetti-Pierri, and F. Scaglia GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects Mol. Genet. Metab. 94 2008 391 396
148. K. Sandhoff, and K. Harzer Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis J. Neurosci. 33 2013 10195 10208
149. A. Caciotti, S.C. Garman, Y. Rivera-Colon, E. Procopio, S. Catarzi, L. Ferri, C. Guido, P. Martelli, R. Parini, D. Antuzzi, R. Battini, M. Sibilio, A. Simonati, E. Fontana, A. Salviati, G. Akinci, C. Cereda, C. Dionisi-Vici, F. Deodato, A. d'Amico, A. d'Azzo, E. Bertini, M. Filocamo, M. Scarpa, M. di Rocco, C.J. Tifft, F. Ciani, S. Gasperini, E. Pasquini, R. Guerrini, M.A. Donati, and A. Morrone GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings Biochim. Biophys. Acta 1812 2011 782 790
150. C.N. Hahn, M. del Pilar Martin, M. Schroder, M.T. Vanier, Y. Hara, K. Suzuki, and A. d'Azzo Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase Hum. Mol. Genet. 6 1997 205 211 (Pubitemid 27078076)
151. J. Matsuda, O. Suzuki, A. Oshima, A. Ogura, Y. Noguchi, Y. Yamamoto, T. Asano, K. Takimoto, K. Sukegawa, Y. Suzuki, and M. Naiki Beta-galactosidase- deficient mouse as an animal model for GM1-gangliosidosis Glycoconj. J. 14 1997 729 736 (Pubitemid 27400104)
152. E. Elliot-Smith, A.O. Speak, E. Lloyd-Evans, D.A. Smith, A.C. van der Spoel, M. Jeyakumar, T.D. Butters, R.A. Dwek, A. d'Azzo, and F.M. Platt Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis Mol. Genet. Metab. 94 2008 204 211
153. R.C. Baek, M.L. Broekman, S.G. Leroy, L.A. Tierney, M.A. Sandberg, A. d'Azzo, T.N. Seyfried, and M. Sena-Esteves AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival PLoS One 5 2010 e13468
154. 2 +-dependent mitochondrial apoptosis Mol. Cell 36 2009 500 511
155. J. Matsuda, O. Suzuki, A. Oshima, Y. Yamamoto, A. Noguchi, K. Takimoto, M. Itoh, Y. Matsuzaki, Y. Yasuda, S. Ogawa, Y. Sakata, E. Nanba, K. Higaki, Y. Ogawa, L. Tominaga, K. Ohno, H. Iwasaki, H. Watanabe, R.O. Brady, and Y. Suzuki Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis Proc. Natl. Acad. Sci. U. S. A. 100 2003 15912 15917 (Pubitemid 38021089)
156. O. Yamato, K. Ochiai, Y. Masuoka, E. Hayashida, M. Tajima, S. Omae, M. Iijima, T. Umemura, and Y. Maede GM1 gangliosidosis in shiba dogs Vet. Rec. 146 2000 493 496
157. Z.H. Wang, B. Zeng, H. Shibuya, G.S. Johnson, J. Alroy, G.M. Pastores, S. Raghavan, and E.H. Kolodny Isolation and characterization of the normal canine beta-galactosidase gene and its mutation in a dog model of GM1-gangliosidosis J. Inherit. Metab. Dis. 23 2000 593 606
158. E.M. Kaye, J. Alroy, S.S. Raghavan, G.A. Schwarting, L.S. Adelman, V. Runge, D. Gelblum, J.G. Thalhammer, and G. Zuniga Dysmyelinogenesis in animal model of GM1 gangliosidosis Pediatr. Neurol. 8 1992 255 261
159. G. Muller, S. Alldinger, A. Moritz, A. Zurbriggen, N. Kirchhof, A. Sewell, and W. Baumgartner GM1-gangliosidosis in Alaskan huskies: clinical and pathologic findings Vet. Pathol. 38 2001 281 290 (Pubitemid 33621787)
160. M.M. Uddin, T. Tanimoto, A. Yabuki, T. Kotani, M. Kuwamura, H.S. Chang, and O. Yamato Mutation analysis of GM1 gangliosidosis in a Siamese cat from Japan in the 1960s J. Feline Med. Surg. 14 2012 900 902
161. R. De Maria, S. Divari, S. Bo, S. Sonnio, D. Lotti, M.T. Capucchio, and M. Castagnaro Beta-galactosidase deficiency in a Korat cat: a new form of feline GM1-gangliosidosis Acta Neuropathol. 96 1998 307 314 (Pubitemid 28419850)
162. S.J. Ryder, and M.M. Simmons A lysosomal storage disease of Romney sheep that resembles human type 3 GM1 gangliosidosis Acta Neuropathol. 101 2001 225 228 (Pubitemid 32219755)
163. R.D. Murnane, W.J. Hartley, and D.J. Prieur Similarity of lectin histochemistry of a lysosomal storage disease in a New Zealand lamb to that of ovine GM1 gangliosidosis Vet. Pathol. 28 1991 332 335
164. R.D. Murnane, A.J. Ahern-Rindell, and D.J. Prieur Ultrastructural lesions of ovine GM1 gangliosidosis Mod. Pathol. 4 1991 755 762
165. W.J. Donnelly, and M. Kelly Leukocyte beta-galactosidase activity in the diagnosis of bovine GM1 gangliosidosis Vet. Rec. 100 1977 318 319
166. W.J. Donnelly, B.J. Sheahan, and T.A. Rogers GM1 gangliosidosis in Friesian calves J. Pathol. 111 1973 173 179
167. M.M. Uddin, S. Arata, Y. Takeuchi, H.S. Chang, K. Mizukami, A. Yabuki, M.M. Rahman, M. Kohyama, M.A. Hossain, K. Takayama, and O. Yamato Molecular epidemiology of canine GM1 gangliosidosis in the Shiba Inu breed in Japan: relationship between regional prevalence and carrier frequency BMC Vet. Res. 9 2013 132
168. J. Alroy, K. Knowles, S.H. Schelling, E.M. Kaye, and A.E. Rosenberg Retarded bone formation in GM1-gangliosidosis: a study of the infantile form and comparison with two canine models Virchows Arch. 426 1995 141 148
169. C.G. Barker, W.F. Blakemore, A. Dell, A.C. Palmer, P.R. Tiller, and B.G. Winchester GM1 gangliosidosis (type 1) in a cat Biochem. J. 235 1986 151 158
170. R. Kreutzer, M. Kreutzer, M.J. Propsting, A.C. Sewell, T. Leeb, H.Y. Naim, and W. Baumgartner Insights into post-translational processing of beta-galactosidase in an animal model resembling late infantile human G-gangliosidosis J. Cell. Mol. Med. 12 2008 1661 1671
171. T. Momoi, T. Furuya, Y. Suzuki, H. Sato, and N. Yamaguchi In vitro establishment of human fibroblasts of lysosomal diseases, GM1-gangliosidosis and Sandhoff disease, by transformation with origin-minus SV40 DNA Biosci. Rep. 5 1985 267 273 (Pubitemid 15117471)
172. D. Phaneuf, N. Wakamatsu, J.Q. Huang, A. Borowski, A.C. Peterson, S.R. Fortunato, G. Ritter, S.A. Igdoura, C.R. Morales, G. Benoit, B.R. Akerman, D. Leclerc, N. Hanai, J.D. Marth, J.M. Trasler, and R.A. Gravel Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases Hum. Mol. Genet. 5 1996 1 14 (Pubitemid 26018268)
173. L.C. Frey, S.P. Ringel, and C.M. Filley The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis Arch. Neurol. 62 2005 989 994 (Pubitemid 40973462)
174. C.J. Hendriksz, P.C. Corry, J.E. Wraith, G.T. Besley, A. Cooper, and C.D. Ferrie Juvenile Sandhoff disease - nine new cases and a review of the literature J. Inherit. Metab. Dis. 27 2004 241 249 (Pubitemid 38756340)
175. S. Yamanaka, M.D. Johnson, A. Grinberg, H. Westphal, J.N. Crawley, M. Taniike, K. Suzuki, and R.L. Proia Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease Proc. Natl. Acad. Sci. U. S. A. 91 1994 9975 9979 (Pubitemid 24311931)
176. M. Cohen-Tannoudji, P. Marchand, S. Akli, S.A. Sheardown, J.P. Puech, C. Kress, P. Gressens, M.C. Nassogne, T. Beccari, and A.L. Muggleton-Harris et al. Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease Mamm. Genome 6 1995 844 849
177. K. Sango, S. Yamanaka, A. Hoffmann, Y. Okuda, A. Grinberg, H. Westphal, M.P. McDonald, J.N. Crawley, K. Sandhoff, K. Suzuki, and R.L. Proia Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism Nat. Genet. 11 1995 170 176
178. Y. Liu, A. Hoffmann, A. Grinberg, H. Westphal, M.P. McDonald, K.M. Miller, J.N. Crawley, K. Sandhoff, K. Suzuki, and R.L. Proia Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment Proc. Natl. Acad. Sci. U. S. A. 94 1997 8138 8143
179. T. Kolter, and K. Sandhoff Glycosphingolipid degradation and animal models of GM2-gangliosidoses J. Inherit. Metab. Dis. 21 1998 548 563 (Pubitemid 28391507)
180. B.J. Zeng, P.A. Torres, T.C. Viner, Z.H. Wang, S.S. Raghavan, J. Alroy, G.M. Pastores, and E.H. Kolodny Spontaneous appearance of Tay-Sachs disease in an animal model Mol. Genet. Metab. 95 2008 59 65
181. M. Jeyakumar, D. Smith, E. Eliott-Smith, M. Cortina-Borja, G. Reinkensmeier, T.D. Butters, T. Lemm, K. Sandhoff, V.H. Perry, R.A. Dwek, and F.M. Platt An inducible mouse model of late onset Tay-Sachs disease Neurobiol. Dis. 10 2002 201 210 (Pubitemid 35217574)
182. E.I. Miklyaeva, W. Dong, A. Bureau, R. Fattahie, Y. Xu, M. Su, G.H. Fick, J.Q. Huang, S. Igdoura, N. Hanai, and R.A. Gravel Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system Brain Res. 1001 2004 37 50 (Pubitemid 38221526)
183. K. Sango, M.P. McDonald, J.N. Crawley, M.L. Mack, C.J. Tifft, E. Skop, C.M. Starr, A. Hoffmann, K. Sandhoff, K. Suzuki, and R.L. Proia Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis Nat. Genet. 14 1996 348 352
184. T.J. Sargeant, D.J. Drage, S. Wang, A.A. Apostolakis, T.M. Cox, and M.B. Cachon-Gonzalez Characterization of inducible models of Tay-Sachs and related disease PLoS Genet. 8 2012 e1002943
185. Y. Ishikawa, S.C. Li, P.A. Wood, and Y.T. Li Biochemical basis of type AB GM2 gangliosidosis in a Japanese spaniel J. Neurochem. 48 1987 860 864 (Pubitemid 17018720)
186. D.N. Sanders, R. Zeng, D.A. Wenger, G.S. Johnson, G.C. Johnson, J.E. Decker, M.L. Katz, S.R. Platt, and D.P. O'Brien GM2 gangliosidosis associated with a HEXA missense mutation in Japanese Chin dogs: a potential model for Tay Sachs disease Mol. Genet. Metab. 108 2013 70 75
187. O. Yamato, N. Matsuki, H. Satoh, M. Inaba, K. Ono, M. Yamasaki, and Y. Maede Sandhoff disease in a golden retriever dog J. Inherit. Metab. Dis. 25 2002 319 320 (Pubitemid 34982065)
188. D. Hasegawa, O. Yamato, M. Kobayashi, M. Fujita, S. Nakamura, K. Takahashi, H. Satoh, T. Shoda, D. Hayashi, M. Yamasaki, Y. Maede, T. Arai, and H. Orima Clinical and molecular analysis of GM2 gangliosidosis in two apparent littermate kittens of the Japanese domestic cat J. Feline Med. Surg. 9 2007 232 237 (Pubitemid 46760358)
189. Y. Kanae, D. Endoh, O. Yamato, D. Hayashi, S. Matsunaga, H. Ogawa, Y. Maede, and M. Hayashi Nonsense mutation of feline beta-hexosaminidase beta-subunit (HEXB) gene causing Sandhoff disease in a family of Japanese domestic cats Res. Vet. Sci. 82 2007 54 60 (Pubitemid 44858078)
190. S.D. Kosanke, K.R. Pierce, and W.W. Bay Clinical and biochemical abnormalities in porcine GM2-gangliosidosis Vet. Pathol. 15 1978 685 699 (Pubitemid 9073013)
191. K.R. Pierce, S.D. Kosanke, W.W. Bay, and C.H. Bridges Animal model of human disease: GM2 gangliosidosis Am. J. Pathol. 83 1976 419 422
192. J. Fox, Y.T. Li, G. Dawson, A. Alleman, J. Johnsrude, J. Schumacher, and B. Homer Naturally occurring GM2 gangliosidosis in two Muntjak deer with pathological and biochemical features of human classical Tay-Sachs disease (type B GM2 gangliosidosis) Acta Neuropathol. 97 1999 57 62 (Pubitemid 29132646)
193. P.A. Torres, B.J. Zeng, B.F. Porter, J. Alroy, F. Horak, J. Horak, and E.H. Kolodny Tay-Sachs disease in Jacob sheep Mol. Genet. Metab. 101 2010 357 363
194. T. Rickmeyer, S. Schoniger, A. Petermann, K. Harzer, B. Kustermann-Kuhn, H. Fuhrmann, and H.A. Schoon GM2 gangliosidosis in an adult pet rabbit J. Comp. Pathol. 148 2013 243 247
195. S.U. Walkley, and K. Dobrenis Bone marrow transplantation for lysosomal diseases Lancet 345 1995 1382 1383
196. L.L. Muldoon, E.A. Neuwelt, M.A. Pagel, and D.L. Weiss Characterization of the molecular defect in a feline model for type II GM2-gangliosidosis (Sandhoff disease) Am J Pathol 144 1994 1109 1118
197. Y. Ogawa, M. Tanaka, M. Tanabe, T. Suzuki, T. Togawa, T. Fukushige, T. Kanekura, H. Sakuraba, and K. Oishi Impaired neural differentiation of induced pluripotent stem cells generated from a mouse model of Sandhoff disease PLoS One 8 2013 e55856
198. T. Ohshima, R. Schiffmann, G.J. Murray, J. Kopp, J.M. Quirk, S. Stahl, C.C. Chan, P. Zerfas, J.H. Tao-Cheng, J.M. Ward, R.O. Brady, and A.B. Kulkarni Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice Proc. Natl. Acad. Sci. U. S. A. 96 1999 6423 6427 (Pubitemid 29256681)